Real-Life Prescribing of SGLT2 Inhibitors : How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Kidney360 - 2(2021), 4 vom: 29. Apr., Seite 742-746 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lam, David [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.04.2022 Date Revised 03.02.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.34067/KID.0000412021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339029145 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339029145 | ||
| 003 | DE-627 | ||
| 005 | 20231226002012.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.34067/KID.0000412021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1130.xml |
| 035 | |a (DE-627)NLM339029145 | ||
| 035 | |a (NLM)35373039 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lam, David |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-Life Prescribing of SGLT2 Inhibitors |b How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.04.2022 | ||
| 500 | |a Date Revised 03.02.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SGLT2i | |
| 650 | 4 | |a diabetes and the kidney | |
| 650 | 4 | |a diabetic kidney disease | |
| 650 | 4 | |a diuretics | |
| 650 | 4 | |a glucose | |
| 650 | 4 | |a pharmaceutical preparations | |
| 650 | 4 | |a sodium-glucose transporter 2 inhibitors | |
| 650 | 7 | |a Diuretics |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 650 | 7 | |a Canagliflozin |2 NLM | |
| 650 | 7 | |a 0SAC974Z85 |2 NLM | |
| 650 | 7 | |a Glucose |2 NLM | |
| 650 | 7 | |a IY9XDZ35W2 |2 NLM | |
| 700 | 1 | |a Shaikh, Aisha |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney360 |d 2020 |g 2(2021), 4 vom: 29. Apr., Seite 742-746 |w (DE-627)NLM311083633 |x 2641-7650 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2021 |g number:4 |g day:29 |g month:04 |g pages:742-746 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.34067/KID.0000412021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2021 |e 4 |b 29 |c 04 |h 742-746 | ||